echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > MSD completed the acquisition of cupist, an antibiotic giant, with us $9.5 billion

    MSD completed the acquisition of cupist, an antibiotic giant, with us $9.5 billion

    • Last Update: 2015-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Biovalley on January 22, 2015, MSD recently announced that it has successfully completed the acquisition of all outstanding common shares of antibiotic giant Cubist at US $102 per share As of January 20, 2015, 58039667 shares of common stock have been effectively tendered, accounting for about 75.7% of Cubist's shares in the outflow With the successful completion of the tender offer, MSD is expected to complete the acquisition by merging into Cubist through a wholly-owned subsidiary later on the 21st Upon completion of the merger, cubist will become a wholly-owned subsidiary of MSD, and its common shares will stop trading on NASDAQ In early December last year, MSD officially announced a final acquisition agreement with Cubist to acquire Cubist at a 35% cash premium of $102 per share The total value of the deal was $9.5 billion, including an equity valuation of $8.4 billion and a net debt of $1.1 billion and other considerations Zerbaxa, the key product of the deal, was approved by the FDA on Christmas Eve last year, which really made MSD happy Zerbaxa (ceftolozane / tazobactam) is also the second FDA approval obtained by Cubist in 2014 On EU regulation, zerbaxa is expected to be approved in the second half of 2015 At present, facing the increasingly severe "antibacterial" situation, some countries have begun to take incentive measures to encourage the research and development of new antibiotics In July 2012, the U.S passed the "encourage the development of Antibiotics Act" (gain) According to the regulations, qualified antibiotic drugs will be granted an additional five years of market monopoly to help developers recover their investment Zebraxa is the first new antibiotic product approved to treat Gram-negative bacteria under the "encourage the development of Antibiotics Act" (gain) On the deal, Mr mosadon said that Cubist is a global leader in the field of antibiotics and has been committed to solving global public health problems through the discovery, development and supply of antibiotics to treat serious potentially life-threatening infections for more than 20 years At present, cubist has established a strong pipeline asset, including listed products and later pipeline products By combining Cubist's expertise in the field of global antibiotics with the strong strength and global influence of MSD, MSD will create a more favorable position in the field of hospital emergency care, while addressing unmet medical needs in key areas, such as antibiotic resistance In addition, the acquisition of Cubist complements the global initiatives and strategies launched by MSD in 2013, especially to enhance the return on investment potential in key treatment areas The acquisition of Cubist will directly increase the company's revenue by $1 billion in 2015  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.